Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

Clinical Trial

doi: 10.1002/art.10294.

Affiliations

PMID: 12115176
DOI: 10.1002/art.10294

Free article

Clinical Trial

Larry W Moreland et al. Arthritis Rheum. 2002 Jun.

Free article

Abstract

Objective: T cells are involved in the pathogenesis of rheumatoid arthritis (RA). In animal models of autoimmune diseases, blockade of costimulatory molecules on antigen-presenting cells has been demonstrated to be effective in preventing or treating this disease by preventing T cell activation. To date, the effect of costimulatory blockade in patients with RA is unknown. The goal of this multicenter, multinational study was to determine the safety and preliminary efficacy of costimulatory blockade using CTLA-4Ig and LEA29Y in RA patients who have been treated unsuccessfully with at least 1 disease-modifying agent.

Methods: CTLA-4Ig, LEA29Y (0.5, 2, or 10 mg/kg), or placebo was administered intravenously to 214 patients with RA. Patients received 4 infusions of study medication, on days 1, 15, 29, and 57, and were evaluated on day 85. The primary end point was the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (ACR20). All patients were monitored for treatment safety and tolerability.

Results: CTLA-4Ig and LEA29Y infusions were well tolerated at all dose levels. Peri-infusional adverse events were carefully monitored, and showed similar incidence across all dose groups with the exception of headaches, which were slightly more frequent in the 2 treatment groups. The incidence of discontinuations due to worsening of RA was 19%, 12%, and 9% at 0.5, 2, and 10 mg/kg, respectively, in the CTLA-4Ig-treated patients and 3%, 3%, and 6% at 0.5, 2, and 10 mg/kg, respectively, in the LEA29Y-treated patients (versus 31% in the placebo group). ACR20 responses on day 85 had increased in a dose-dependent manner (23%, 44%, and 53% of CTLA-4Ig-treated patients and 34%, 45%, and 61% of LEA29Y-treated patients at 0.5, 2.0, and 10 mg/kg, respectively, versus 31% of placebo-treated patients).

Conclusion: Both of the costimulatory blocking molecules studied were generally safe and well tolerated. As compared with placebo, both CTLA-4Ig and LEA29Y demonstrated efficacy in the treatment of RA.

PubMed Disclaimer

Cited by

[Biologics therapy for systemic lupus erythematosus. Current situation].
Hoyer BF, Dörner T. Hoyer BF, et al. Z Rheumatol. 2015 Apr;74(3):206-14. doi: 10.1007/s00393-014-1458-0. Z Rheumatol. 2015. PMID: 25854155 Review. German.
T cell tolerance induced by therapeutic antibodies.
Cobbold SP. Cobbold SP. Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1695-705. doi: 10.1098/rstb.2005.1698. Philos Trans R Soc Lond B Biol Sci. 2005. PMID: 16147534 Free PMC article. Review.
Modulating co-stimulation.
Viglietta V, Khoury SJ. Viglietta V, et al. Neurotherapeutics. 2007 Oct;4(4):666-75. doi: 10.1016/j.nurt.2007.07.006. Neurotherapeutics. 2007. PMID: 17920548 Free PMC article. Review.
The role of the T cell in autoimmune inflammation.
Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. Skapenko A, et al. Arthritis Res Ther. 2005;7 Suppl 2(Suppl 2):S4-14. doi: 10.1186/ar1703. Epub 2005 Mar 16. Arthritis Res Ther. 2005. PMID: 15833146 Free PMC article. Review.
Citrullination in the pathology of inflammatory and autoimmune disorders: recent advances and future perspectives.
Ciesielski O, Biesiekierska M, Panthu B, Soszyński M, Pirola L, Balcerczyk A. Ciesielski O, et al. Cell Mol Life Sci. 2022 Jan 25;79(2):94. doi: 10.1007/s00018-022-04126-3. Cell Mol Life Sci. 2022. PMID: 35079870 Free PMC article. Review.

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion - PubMed (original) (raw)